Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging...
Ausführliche Beschreibung
Autor*in: |
Bryce J. B. Nelson [verfasserIn] John Wilson [verfasserIn] Jan D. Andersson [verfasserIn] Frank Wuest [verfasserIn] |
---|
Format: |
E-Artikel |
---|---|
Sprache: |
Englisch |
Erschienen: |
2023 |
---|
Schlagwörter: |
---|
Übergeordnetes Werk: |
In: Pharmaceuticals - MDPI AG, 2005, 16(2023), 11, p 1622 |
---|---|
Übergeordnetes Werk: |
volume:16 ; year:2023 ; number:11, p 1622 |
Links: |
---|
DOI / URN: |
10.3390/ph16111622 |
---|
Katalog-ID: |
DOAJ101201524 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | DOAJ101201524 | ||
003 | DE-627 | ||
005 | 20240414151746.0 | ||
007 | cr uuu---uuuuu | ||
008 | 240414s2023 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.3390/ph16111622 |2 doi | |
035 | |a (DE-627)DOAJ101201524 | ||
035 | |a (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
050 | 0 | |a RS1-441 | |
100 | 0 | |a Bryce J. B. Nelson |e verfasserin |4 aut | |
245 | 1 | 0 | |a Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications |
264 | 1 | |c 2023 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a Computermedien |b c |2 rdamedia | ||
338 | |a Online-Ressource |b cr |2 rdacarrier | ||
520 | |a This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. | ||
650 | 4 | |a targeted alpha therapy | |
650 | 4 | |a alpha particle therapy | |
650 | 4 | |a PET imaging | |
650 | 4 | |a SPECT imaging | |
650 | 4 | |a targeted radionuclide therapy | |
650 | 4 | |a theranostics | |
653 | 0 | |a Medicine | |
653 | 0 | |a R | |
653 | 0 | |a Pharmacy and materia medica | |
700 | 0 | |a John Wilson |e verfasserin |4 aut | |
700 | 0 | |a Jan D. Andersson |e verfasserin |4 aut | |
700 | 0 | |a Frank Wuest |e verfasserin |4 aut | |
773 | 0 | 8 | |i In |t Pharmaceuticals |d MDPI AG, 2005 |g 16(2023), 11, p 1622 |w (DE-627)491437528 |w (DE-600)2193542-7 |x 14248247 |7 nnns |
773 | 1 | 8 | |g volume:16 |g year:2023 |g number:11, p 1622 |
856 | 4 | 0 | |u https://doi.org/10.3390/ph16111622 |z kostenfrei |
856 | 4 | 0 | |u https://doaj.org/article/12642c086c284c19a514aa360b6fb03c |z kostenfrei |
856 | 4 | 0 | |u https://www.mdpi.com/1424-8247/16/11/1622 |z kostenfrei |
856 | 4 | 2 | |u https://doaj.org/toc/1424-8247 |y Journal toc |z kostenfrei |
912 | |a GBV_USEFLAG_A | ||
912 | |a SYSFLAG_A | ||
912 | |a GBV_DOAJ | ||
912 | |a GBV_ILN_20 | ||
912 | |a GBV_ILN_22 | ||
912 | |a GBV_ILN_23 | ||
912 | |a GBV_ILN_24 | ||
912 | |a GBV_ILN_39 | ||
912 | |a GBV_ILN_40 | ||
912 | |a GBV_ILN_60 | ||
912 | |a GBV_ILN_62 | ||
912 | |a GBV_ILN_63 | ||
912 | |a GBV_ILN_65 | ||
912 | |a GBV_ILN_69 | ||
912 | |a GBV_ILN_73 | ||
912 | |a GBV_ILN_74 | ||
912 | |a GBV_ILN_95 | ||
912 | |a GBV_ILN_105 | ||
912 | |a GBV_ILN_110 | ||
912 | |a GBV_ILN_151 | ||
912 | |a GBV_ILN_161 | ||
912 | |a GBV_ILN_170 | ||
912 | |a GBV_ILN_206 | ||
912 | |a GBV_ILN_213 | ||
912 | |a GBV_ILN_230 | ||
912 | |a GBV_ILN_285 | ||
912 | |a GBV_ILN_293 | ||
912 | |a GBV_ILN_602 | ||
912 | |a GBV_ILN_2005 | ||
912 | |a GBV_ILN_2009 | ||
912 | |a GBV_ILN_2011 | ||
912 | |a GBV_ILN_2014 | ||
912 | |a GBV_ILN_2055 | ||
912 | |a GBV_ILN_2111 | ||
912 | |a GBV_ILN_4012 | ||
912 | |a GBV_ILN_4037 | ||
912 | |a GBV_ILN_4112 | ||
912 | |a GBV_ILN_4125 | ||
912 | |a GBV_ILN_4126 | ||
912 | |a GBV_ILN_4249 | ||
912 | |a GBV_ILN_4305 | ||
912 | |a GBV_ILN_4306 | ||
912 | |a GBV_ILN_4307 | ||
912 | |a GBV_ILN_4313 | ||
912 | |a GBV_ILN_4322 | ||
912 | |a GBV_ILN_4323 | ||
912 | |a GBV_ILN_4324 | ||
912 | |a GBV_ILN_4325 | ||
912 | |a GBV_ILN_4338 | ||
912 | |a GBV_ILN_4367 | ||
912 | |a GBV_ILN_4700 | ||
951 | |a AR | ||
952 | |d 16 |j 2023 |e 11, p 1622 |
author_variant |
b j b n bjbn j w jw j d a jda f w fw |
---|---|
matchkey_str |
article:14248247:2023----::hrnsiiaigurgtsotreeapahrpporsipoutop |
hierarchy_sort_str |
2023 |
callnumber-subject-code |
RS |
publishDate |
2023 |
allfields |
10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622 |
spelling |
10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622 |
allfields_unstemmed |
10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622 |
allfieldsGer |
10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622 |
allfieldsSound |
10.3390/ph16111622 doi (DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c DE-627 ger DE-627 rakwb eng RS1-441 Bryce J. B. Nelson verfasserin aut Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications 2023 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica John Wilson verfasserin aut Jan D. Andersson verfasserin aut Frank Wuest verfasserin aut In Pharmaceuticals MDPI AG, 2005 16(2023), 11, p 1622 (DE-627)491437528 (DE-600)2193542-7 14248247 nnns volume:16 year:2023 number:11, p 1622 https://doi.org/10.3390/ph16111622 kostenfrei https://doaj.org/article/12642c086c284c19a514aa360b6fb03c kostenfrei https://www.mdpi.com/1424-8247/16/11/1622 kostenfrei https://doaj.org/toc/1424-8247 Journal toc kostenfrei GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 AR 16 2023 11, p 1622 |
language |
English |
source |
In Pharmaceuticals 16(2023), 11, p 1622 volume:16 year:2023 number:11, p 1622 |
sourceStr |
In Pharmaceuticals 16(2023), 11, p 1622 volume:16 year:2023 number:11, p 1622 |
format_phy_str_mv |
Article |
institution |
findex.gbv.de |
topic_facet |
targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics Medicine R Pharmacy and materia medica |
isfreeaccess_bool |
true |
container_title |
Pharmaceuticals |
authorswithroles_txt_mv |
Bryce J. B. Nelson @@aut@@ John Wilson @@aut@@ Jan D. Andersson @@aut@@ Frank Wuest @@aut@@ |
publishDateDaySort_date |
2023-01-01T00:00:00Z |
hierarchy_top_id |
491437528 |
id |
DOAJ101201524 |
language_de |
englisch |
fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101201524</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414151746.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ph16111622</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101201524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ12642c086c284c19a514aa360b6fb03c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bryce J. B. Nelson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted alpha therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">alpha particle therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PET imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SPECT imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted radionuclide therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">theranostics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan D. Andersson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frank Wuest</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmaceuticals</subfield><subfield code="d">MDPI AG, 2005</subfield><subfield code="g">16(2023), 11, p 1622</subfield><subfield code="w">(DE-627)491437528</subfield><subfield code="w">(DE-600)2193542-7</subfield><subfield code="x">14248247</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11, p 1622</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ph16111622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/12642c086c284c19a514aa360b6fb03c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1424-8247/16/11/1622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1424-8247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">11, p 1622</subfield></datafield></record></collection>
|
callnumber-first |
R - Medicine |
author |
Bryce J. B. Nelson |
spellingShingle |
Bryce J. B. Nelson misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications |
authorStr |
Bryce J. B. Nelson |
ppnlink_with_tag_str_mv |
@@773@@(DE-627)491437528 |
format |
electronic Article |
delete_txt_mv |
keep |
author_role |
aut aut aut aut |
collection |
DOAJ |
remote_str |
true |
callnumber-label |
RS1-441 |
illustrated |
Not Illustrated |
issn |
14248247 |
topic_title |
RS1-441 Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications targeted alpha therapy alpha particle therapy PET imaging SPECT imaging targeted radionuclide therapy theranostics |
topic |
misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica |
topic_unstemmed |
misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica |
topic_browse |
misc RS1-441 misc targeted alpha therapy misc alpha particle therapy misc PET imaging misc SPECT imaging misc targeted radionuclide therapy misc theranostics misc Medicine misc R misc Pharmacy and materia medica |
format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
format_main_str_mv |
Text Zeitschrift/Artikel |
carriertype_str_mv |
cr |
hierarchy_parent_title |
Pharmaceuticals |
hierarchy_parent_id |
491437528 |
hierarchy_top_title |
Pharmaceuticals |
isfreeaccess_txt |
true |
familylinks_str_mv |
(DE-627)491437528 (DE-600)2193542-7 |
title |
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications |
ctrlnum |
(DE-627)DOAJ101201524 (DE-599)DOAJ12642c086c284c19a514aa360b6fb03c |
title_full |
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications |
author_sort |
Bryce J. B. Nelson |
journal |
Pharmaceuticals |
journalStr |
Pharmaceuticals |
callnumber-first-code |
R |
lang_code |
eng |
isOA_bool |
true |
recordtype |
marc |
publishDateSort |
2023 |
contenttype_str_mv |
txt |
author_browse |
Bryce J. B. Nelson John Wilson Jan D. Andersson Frank Wuest |
container_volume |
16 |
class |
RS1-441 |
format_se |
Elektronische Aufsätze |
author-letter |
Bryce J. B. Nelson |
doi_str_mv |
10.3390/ph16111622 |
author2-role |
verfasserin |
title_sort |
theranostic imaging surrogates for targeted alpha therapy: progress in production, purification, and applications |
callnumber |
RS1-441 |
title_auth |
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications |
abstract |
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. |
abstractGer |
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. |
abstract_unstemmed |
This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT. |
collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_DOAJ GBV_ILN_20 GBV_ILN_22 GBV_ILN_23 GBV_ILN_24 GBV_ILN_39 GBV_ILN_40 GBV_ILN_60 GBV_ILN_62 GBV_ILN_63 GBV_ILN_65 GBV_ILN_69 GBV_ILN_73 GBV_ILN_74 GBV_ILN_95 GBV_ILN_105 GBV_ILN_110 GBV_ILN_151 GBV_ILN_161 GBV_ILN_170 GBV_ILN_206 GBV_ILN_213 GBV_ILN_230 GBV_ILN_285 GBV_ILN_293 GBV_ILN_602 GBV_ILN_2005 GBV_ILN_2009 GBV_ILN_2011 GBV_ILN_2014 GBV_ILN_2055 GBV_ILN_2111 GBV_ILN_4012 GBV_ILN_4037 GBV_ILN_4112 GBV_ILN_4125 GBV_ILN_4126 GBV_ILN_4249 GBV_ILN_4305 GBV_ILN_4306 GBV_ILN_4307 GBV_ILN_4313 GBV_ILN_4322 GBV_ILN_4323 GBV_ILN_4324 GBV_ILN_4325 GBV_ILN_4338 GBV_ILN_4367 GBV_ILN_4700 |
container_issue |
11, p 1622 |
title_short |
Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications |
url |
https://doi.org/10.3390/ph16111622 https://doaj.org/article/12642c086c284c19a514aa360b6fb03c https://www.mdpi.com/1424-8247/16/11/1622 https://doaj.org/toc/1424-8247 |
remote_bool |
true |
author2 |
John Wilson Jan D. Andersson Frank Wuest |
author2Str |
John Wilson Jan D. Andersson Frank Wuest |
ppnlink |
491437528 |
callnumber-subject |
RS - Pharmacy |
mediatype_str_mv |
c |
isOA_txt |
true |
hochschulschrift_bool |
false |
doi_str |
10.3390/ph16111622 |
callnumber-a |
RS1-441 |
up_date |
2024-07-03T19:14:42.030Z |
_version_ |
1803586457603932161 |
fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">DOAJ101201524</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20240414151746.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">240414s2023 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.3390/ph16111622</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)DOAJ101201524</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)DOAJ12642c086c284c19a514aa360b6fb03c</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="050" ind1=" " ind2="0"><subfield code="a">RS1-441</subfield></datafield><datafield tag="100" ind1="0" ind2=" "><subfield code="a">Bryce J. B. Nelson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Theranostic Imaging Surrogates for Targeted Alpha Therapy: Progress in Production, Purification, and Applications</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2023</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">This article highlights recent developments of SPECT and PET diagnostic imaging surrogates for targeted alpha particle therapy (TAT) radiopharmaceuticals. It outlines the rationale for using imaging surrogates to improve diagnostic-scan accuracy and facilitate research, and the properties an imaging-surrogate candidate should possess. It evaluates the strengths and limitations of each potential imaging surrogate. Thirteen surrogates for TAT are explored: <sup<133</sup<La, <sup<132</sup<La, <sup<134</sup<Ce/<sup<134</sup<La, and <sup<226</sup<Ac for <sup<225</sup<Ac TAT; <sup<203</sup<Pb for <sup<212</sup<Pb TAT; <sup<131</sup<Ba for <sup<223</sup<Ra and <sup<224</sup<Ra TAT; <sup<123</sup<I, <sup<124</sup<I, <sup<131</sup<I and <sup<209</sup<At for <sup<211</sup<At TAT; <sup<134</sup<Ce/<sup<134</sup<La for <sup<227</sup<Th TAT; and <sup<155</sup<Tb and <sup<152</sup<Tb for <sup<149</sup<Tb TAT.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted alpha therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">alpha particle therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">PET imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">SPECT imaging</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">targeted radionuclide therapy</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">theranostics</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Medicine</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">R</subfield></datafield><datafield tag="653" ind1=" " ind2="0"><subfield code="a">Pharmacy and materia medica</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">John Wilson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Jan D. Andersson</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="0" ind2=" "><subfield code="a">Frank Wuest</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">In</subfield><subfield code="t">Pharmaceuticals</subfield><subfield code="d">MDPI AG, 2005</subfield><subfield code="g">16(2023), 11, p 1622</subfield><subfield code="w">(DE-627)491437528</subfield><subfield code="w">(DE-600)2193542-7</subfield><subfield code="x">14248247</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:16</subfield><subfield code="g">year:2023</subfield><subfield code="g">number:11, p 1622</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doi.org/10.3390/ph16111622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://doaj.org/article/12642c086c284c19a514aa360b6fb03c</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://www.mdpi.com/1424-8247/16/11/1622</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="856" ind1="4" ind2="2"><subfield code="u">https://doaj.org/toc/1424-8247</subfield><subfield code="y">Journal toc</subfield><subfield code="z">kostenfrei</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_DOAJ</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_20</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_22</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_23</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_24</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_39</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_40</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_60</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_62</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_63</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_65</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_69</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_73</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_74</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_95</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_105</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_110</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_151</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_161</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_170</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_206</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_213</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_230</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_285</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_293</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_602</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2005</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2009</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2011</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2014</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2055</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_2111</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4012</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4037</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4112</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4125</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4126</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4249</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4305</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4306</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4307</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4313</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4322</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4323</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4324</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4325</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4338</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4367</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_ILN_4700</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">16</subfield><subfield code="j">2023</subfield><subfield code="e">11, p 1622</subfield></datafield></record></collection>
|
score |
7.399946 |